Tango Therapeutics names new CFO and finance lead
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline. The board decided that Daniella Beckman will step down as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
Effective the same date, Matthew Gall becomes Chief Financial Officer and principal financial officer under an employment agreement that includes an option for 240,000 shares and 40,000 restricted stock units, subject to time-based vesting and continued employment. Jessica Newcomb is appointed principal accounting officer, while a related press release highlights additional senior hires in development operations and corporate strategy to help advance vopimetostat toward potential regulatory approval in pancreatic cancer.
Insights
CFO transition and new senior hires support late-stage focus.
Tango Therapeutics is replacing long-time CFO Daniella Beckman with Matthew Gall and elevating Jessica Newcomb to principal accounting officer. The press release also adds leaders for development operations and corporate strategy around vopimetostat, its PRMT5 inhibitor.
These moves align financial, operational and strategic leadership with late-stage development and potential commercialization goals. Equity incentives for the new CFO, including options and restricted stock units, help link his compensation to long-term company performance.
8-K Event Classification
Key Figures
Key Terms
restricted stock units financial
2023 Inducement Plan financial
principal financial officer financial
clinical-stage biotechnology company technical
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership changes did Tango Therapeutics (TNGX) announce in this 8-K?
Who is the new Chief Financial Officer of Tango Therapeutics (TNGX)?
What equity awards is Tango Therapeutics granting to new CFO Matthew Gall?
Who is the new principal accounting officer at Tango Therapeutics (TNGX)?
What additional senior hires did Tango Therapeutics announce for vopimetostat development?
What is vopimetostat in Tango Therapeutics’ pipeline?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Chief Financial Officer
On April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.
Appointment of Chief Financial Officer
On April 10, 2026, the Board appointed Matthew Gall, MBA, 49, as the Company’s Chief Financial Officer and principal financial officer effective as of April 15, 2026.
Mr. Gall previously served as Chief Financial Officer of Kalaris Therapeutics, Inc. from November 2025 to April 2026. Prior to that, Mr. Gall served as the Chief Financial Officer of iTeos Theraputics, Inc., a clinical-stage biopharmaceutical company, from June 2020 to August 2025 and he held various roles at Sarepta Therapeutics, Inc., a commercial-stage biotechnology company, from January 2012 to June 2020. Mr. Gall holds a B.S. in Business Administration from Bowling Green State University and an M.B.A. from The University of Chicago Booth School of Business.
In connection with his appointment as Chief Financial Officer, Mr. Gall entered into an employment agreement with the Company (the “Employment Agreement”), effective April 15, 2026. Pursuant to the terms of the Employment Agreement, Mr. Gall will be entitled to:
| • | Annual base salary of $540,000; |
| • | Target cash bonus opportunity of 40% of his current annual base salary, pro-rated for any partial calendar year of service. |
The foregoing description of the terms and conditions of the Employment Agreement does not purport to be complete and is qualified in its entirety by the Employment Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Mr. Gall has also entered into the Company’s standard form of indemnification agreement, which was filed as Exhibit 10.10 to the Company’s Current Report on Form 8-K filed on August 13, 2021.
In connection with his appointment as Chief Financial Officer, Mr. Gall will be granted (i) an option to purchase 240,000 shares of the Company’s common stock under the Company’s 2023 Inducement Plan at an exercise price equal to the closing price of the Company’s common stock as reported on The Nasdaq Global Market on May 1, 2026 , which will vest as to 25% of the shares underlying the option on the one year anniversary of the start of Mr. Gall’s employment, and the remainder vesting in 36 monthly thereafter, and (ii) restricted stock units to acquire 40,000 shares of the Company’s common stock, which shares will vest in three approximately equal annual installments in accordance with Company’s equity incentive policies, in each case, subject to Mr. Gall’s continued employment with the Company.
There are no understandings or arrangements between Mr. Gall and any other person pursuant to which he was appointed as the Company’s Chief Financial Officer. Except as described above, Mr. Gall does not have any material interest in any transaction or proposed transaction in which the Company is or is to be a party. Mr. Gall does not have a family relationship with any other director or executive officer of the Company.
Appointment of Principal Accounting Officer
On April 10, 2026, the Board appointed Jessica Newcomb, 40, to serve as the Company’s principal accounting officer effective as of April 15, 2026.
Ms. Newcomb currently serves as Senior Vice President, Finance at the Company. She joined the Company in August 2022 and previously served as Vice President, Finance. Prior to joining the Company, Ms. Newcomb held roles of increasing responsibility and ultimately as VP, Corporate Controller at Acceleron Pharma, Inc., a biotechnology company that was acquired by Merck & Co, from March 2019 to May 2022. Ms. Newcomb began her career at Ernst & Young LLP. Ms. Newcomb received her B.S. in Business Administration, Accounting, and Marketing and her M.S.A. in Accounting from the Boston College Carroll School of Management. Ms. Newcomb is a certified public accountant in the Commonwealth of Massachusetts.
There are no understandings or arrangements between Ms. Newcomb and any other person pursuant to which she was appointed as the Company’s principal accounting officer. Except as described above, Ms. Newcomb does not have any material interest in any transaction or proposed transaction in which the Company is or is to be a party. Ms. Newcomb does not have a family relationship with any other director or executive officer of the Company.
| Item 7.01 | Regulation FD Disclosures. |
On April 15, 2026, the Company issued a press release announcing the leadership changes described above. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing, unless specifically stated so therein.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
Description of Exhibit | |
| 10.1 | Employment Agreement, dated as of April 15, 2026 by and between the Company and Matthew Gall. | |
| 99.1 | Press release, dated April 15, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Tango Therapeutics, Inc. | ||||||
| Date: April 15, 2026 | /s/ Malte Peters | |||||
| Malte Peters, M.D. | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
- Matthew Gall appointed Chief Financial Officer -
- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership.
“Building on our longstanding scientific leadership and recent clinical progress, Tango has a unique opportunity with vopimetostat to bring a potentially paradigm-shifting treatment to patients with pancreatic and other cancers,” said Malte Peters, MD, President and Chief Executive Officer. “In order to support our goal and drive Tango’s next phase of growth, we have strengthened our development, corporate strategy and finance leadership to accelerate and support our efforts in late-stage development and potential commercialization. I extend my gratitude to our prior Chief Financial Officer, Daniella Beckman, for her many contributions to Tango since its inception, including taking the Company public and leading multiple capital raises. We wish her well in future endeavors. We look forward to presenting key clinical data this year, including initial data from our combination trial with Revolution Medicines, Inc.’s RAS(ON) inhibitors.”
Matthew Gall has been appointed Chief Financial Officer effective April 15, succeeding Daniella Beckman. Mr. Gall is a seasoned biotechnology executive with extensive finance, corporate development, strategic transaction and capital raising experience. Previously, he was Chief Financial Officer at Kalaris Therapeutics and iTeos Therapeutics, and held finance, business development and corporate strategy roles at Sarepta Therapeutics, Celgene Corporation and Gilead Sciences.
Yen-Ching Chua has been appointed Chief Development Operations Officer effective June 1, overseeing clinical operations including data management, as well as quality, clinical compliance and clinical sourcing. She brings deep global experience, having previously led clinical and development operations across complex global portfolios at Novocure, Debiopharm International, MorphoSys and Novartis.
In addition, Janice Kapty, PhD has been appointed SVP, Corporate Strategy and Project Leadership, effective April 15. In this role, she will be responsible for portfolio strategy, oversee the project management organization, and ensure strong project leadership for vopimetostat and portfolio therapies, including TNG456. Previously, Dr. Kapty led drug development teams at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene Corporation.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango and members of the Tango senior management team. Forward-looking statements are not purely historical and may be accompanied by words such as “may,” “should,” “expect,” “intend,” “will,” “goal,” “estimate,” “anticipate,” “believe,” “predict,” “designed,” “potential,” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: Dr. Peters’s statements in this press release and statements regarding: (i) the potential of the Company’s PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors, including our belief that vopimetostat has the potential to provide a paradigm-shifting treatment to patients with pancreatic and other cancers; (ii) expectations regarding the anticipated benefits of our molecules and the potential regulatory approval of vopimetostat; (iii) the anticipated impact of the management changes described herein; (iv) timing for disclosing initial, interim, updated, additional and final clinical trial results (including for combination studies), including expectations to present clinical updates for vopimetostat in combination with Revolution Medicine’s RAS(ON) inhibitors in 2026. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango may not be able to commence its clinical trials when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate or report clinical trial results (including final, initial, interim, or updated clinical trial results or additional safety and efficacy data and the establishment of proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); future clinical trial data releases may differ materially from initial or interim data from our
current and future clinical trials; the expected benefits of our product candidates in patients as single agents and/or in combination may not be realized; government regulation may negatively impact Tango’s business; inadequate funding for or disruptions at the U.S. Food and Drug Administration or other government agencies may slow the time necessary for new drugs to be reviewed and/or approved or prevent these agencies from performing business functions on which the operation of our business may rely (which could negatively impact our business). Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.
Investors:
Elizabeth Hickin
ehickin@tangotx.com
Media:
1AB media
Amanda Lazaro
amanda@1abmedia.com